Miniatura

Fitxers

669460.pdf (803.65 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2016-01-01

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/108895

Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1200/JCO.2015.62.9337

Resum

Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden. Patients and Methods Through prospective evaluation of 1,334 patients with PV who had characterized symptom burden, we assessed patient demographics, laboratory data, and the presence of splenomegaly by disease feature (ie, known HU use, known phlebotomy requirements, splenomegaly). Results The presence of each feature in itself is associated with a moderately high symptom burden (MPN symptom assessment form [SAF] total symptom score [TSS] range, 27.7 to 29.2) that persists independent of PV risk category. In addition, symptoms incrementally increase in severity with the addition of other features. Patients with PV who had all three features (PV-HUPS) faced the highest total score (MPN-SAF TSS, 32.5) but had similar individual symptom scores to patients with known HU use (PV-HU), known phlebotomy (PV-P), and splenomegaly (PV-S). Conclusion The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present.

Matèries

Hematologia, Oncologia, Medul·la òssia, Malalties hematològiques

Matèries (anglès)

Hematology, Oncology, Bone marrow, Hematologic diseases

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

GEYER, Holly l., SCHERBER, Robyn, KOSIOREK, Heidi, DUECK, Amylou c., KILADJIAN, Jean-jacques, XIAO, Zhijian, SLOT, Stefanie, ZWEEGMAN, Sonja, SACKMANN, Federico, KERGUELEN FUENTES, Ana, HERNÁNDEZ-MARAVER, Dolores, DÖHNER, Konstanze, HARRISON, Claire n., RADIA, Deepti, MUXI, Pablo, BESSES, Carlos, CERVANTES REQUENA, F., JOHANSSON, Peter l., ANDREASSON, Bjorn, RAMBALDI, Alessandro, BARBUI, Tiziano, BONATZ, Karin, REITER, Andreas, BOYER, Francoise, ETIENNE, Gabriel, IANOTTO, Jean-christophe, RANTA, Dana, ROY, Lydia, CAHN, Jean-yves, MALDONADO, Norman, BAROSI, Giovanni, FERRARI, Maria l., GALE, Robert peter, BIRGEGARD, Gunnar, XU, Zefeng, ZHANG, Yue, SUN, Xiujuan, XU, Junqing, ZHANG, Peihong, TE BOEKHORST, Peter a., COMMANDEUR, Suzan, SCHOUTEN, Harry c., PAHL, Heike l., GRIESSHAMMER, Martin, STEGELMANN, Frank, LEHMANN, Thomas, SENYAK, Zhenya, VANNUCCHI, Alessandro m., PASSAMONTI, Francesco, SAMUELSSON, Jan, MESA, Ruben a.. Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease. _Journal of Clinical Oncology_. 2016. Vol. 34, núm. 2, pàgs. 151-159. [consulta: 21 de gener de 2026]. ISSN: 0732-183X. [Disponible a: https://hdl.handle.net/2445/108895]

Exportar metadades

JSON - METS

Compartir registre